MX357227B - Nanoparticulas basadas en lipidos. - Google Patents

Nanoparticulas basadas en lipidos.

Info

Publication number
MX357227B
MX357227B MX2013011231A MX2013011231A MX357227B MX 357227 B MX357227 B MX 357227B MX 2013011231 A MX2013011231 A MX 2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A MX 357227 B MX357227 B MX 357227B
Authority
MX
Mexico
Prior art keywords
compositions
lipid
based nanoparticles
amyloid
liposomal
Prior art date
Application number
MX2013011231A
Other languages
English (en)
Other versions
MX2013011231A (es
Inventor
Annapragada Ananth
L Eriksen Jason
A Tanifum Eric
Dasgupta Indrani
c cook Stephen
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX357227(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2013011231A publication Critical patent/MX2013011231A/es
Publication of MX357227B publication Critical patent/MX357227B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Se proporcionan composiciones de nanopartículas basadas en lípidos. Las composiciones generalmente comprenden conjugados de ligando de unión a amiloide con polímero hidrofílico y lípido, y pueden ser composiciones liposómicas. Las composiciones, incluyendo las composiciones liposómicas, pueden ser útiles para la formación de Imágenes y para el tratamiento de los depósitos de la placa ß-amiloide característicos de la Enfermedad de Alzheimer.
MX2013011231A 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos. MX357227B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Publications (2)

Publication Number Publication Date
MX2013011231A MX2013011231A (es) 2015-03-05
MX357227B true MX357227B (es) 2018-07-02

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011231A MX357227B (es) 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos.

Country Status (15)

Country Link
US (1) US9801957B2 (es)
EP (2) EP2694116B1 (es)
JP (3) JP6212032B2 (es)
KR (2) KR102035187B1 (es)
CN (1) CN104144708B (es)
AU (3) AU2012239888B9 (es)
BR (1) BR112013025633A2 (es)
CA (1) CA2831480C (es)
DK (1) DK2694116T3 (es)
ES (1) ES2685824T3 (es)
HK (1) HK1203827A1 (es)
MX (1) MX357227B (es)
PL (1) PL2694116T3 (es)
PT (1) PT2694116T (es)
WO (1) WO2012139080A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104144708B (zh) * 2011-04-06 2017-07-28 德克萨斯大学***董事会 基于脂质的纳米粒子
CN104081416B (zh) 2012-01-20 2018-10-02 A·安那普拉加达 用于客观地表征医学图像的方法和组合物
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
ES2743704T3 (es) * 2014-10-08 2020-02-20 Texas Childrens Hospital Obtención de imágenes de IRM de la placa amiloide usando liposomas
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
WO2017201091A1 (en) * 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
CN110022859B (zh) 2016-11-30 2022-10-28 德克萨斯州儿童医院 具有独特的mr特征用于脂质体19f mri探针的亲水性氟化分子
US20200261605A1 (en) * 2019-01-24 2020-08-20 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
EP4096722A4 (en) * 2020-01-29 2023-06-28 Texas Children's Hospital Targeted contrast agents for mri of amyloid deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
EP4103239A4 (en) * 2020-02-12 2024-03-20 Texas Children's Hospital TARGETED CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING OF ALPHA-SYNUCLEIN DEPOSITS

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
WO1995026205A1 (en) 1994-03-28 1995-10-05 Nycomed Imaging A/S Liposomes
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
US6989153B2 (en) 1999-11-30 2006-01-24 Varian Medical Systems Technologies, Inc. Radiation sensitive liposomes
WO2002028441A2 (en) * 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US7138136B2 (en) 2002-03-05 2006-11-21 Cleveland State University Agglomerated particles for aerosol drug delivery
US7605182B2 (en) 2003-05-01 2009-10-20 Aposense Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US7803351B2 (en) * 2004-08-20 2010-09-28 Washington University Blood brain barrier permeation peptides
ATE493152T1 (de) * 2004-09-23 2011-01-15 Guerbet Sa Liposomale kontrastmittel für die cest-bildgebung
EP1888034A2 (en) * 2005-05-26 2008-02-20 Yissum Research Development Company, of The Hebrew University of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2008054498A2 (en) 2006-04-07 2008-05-08 The Board Of Trustees Of The University Of Illinois Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
AU2008278605A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
AU2008331764A1 (en) 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
AU2009257279A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2410990A4 (en) 2009-03-19 2015-05-20 Marval Biosciences Inc COMPOSITIONS AND METHODS FOR CONTRAST GAINING IN IMAGING
US9334304B2 (en) * 2009-04-02 2016-05-10 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
ES2913069T3 (es) 2011-03-02 2022-05-31 Sensulin Llc Composiciones de vesículas
CN104144708B (zh) 2011-04-06 2017-07-28 德克萨斯大学***董事会 基于脂质的纳米粒子
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CN104081416B (zh) 2012-01-20 2018-10-02 A·安那普拉加达 用于客观地表征医学图像的方法和组合物
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
ES2743704T3 (es) 2014-10-08 2020-02-20 Texas Childrens Hospital Obtención de imágenes de IRM de la placa amiloide usando liposomas

Also Published As

Publication number Publication date
JP6212032B2 (ja) 2017-10-18
CN104144708B (zh) 2017-07-28
AU2012239888A2 (en) 2014-05-08
AU2012239888B2 (en) 2017-06-22
PL2694116T3 (pl) 2018-12-31
KR102035187B1 (ko) 2019-11-08
PT2694116T (pt) 2018-10-12
CA2831480A1 (en) 2012-10-11
KR101973063B1 (ko) 2019-04-30
EP3366313A1 (en) 2018-08-29
US9801957B2 (en) 2017-10-31
JP6533813B2 (ja) 2019-06-19
AU2017232156C1 (en) 2019-10-24
WO2012139080A3 (en) 2014-05-01
KR20140074868A (ko) 2014-06-18
JP2014523854A (ja) 2014-09-18
HK1203827A1 (en) 2015-11-06
BR112013025633A2 (pt) 2017-08-08
WO2012139080A2 (en) 2012-10-11
JP2018035167A (ja) 2018-03-08
EP2694116B1 (en) 2018-06-13
AU2017232156B2 (en) 2019-07-11
AU2017232156A1 (en) 2017-10-12
JP2019151664A (ja) 2019-09-12
AU2012239888B9 (en) 2017-10-12
EP2694116A2 (en) 2014-02-12
ES2685824T3 (es) 2018-10-11
US20120258044A1 (en) 2012-10-11
EP2694116A4 (en) 2015-06-03
AU2012239888A1 (en) 2013-11-07
MX2013011231A (es) 2015-03-05
AU2019246775A1 (en) 2019-10-31
KR20190031334A (ko) 2019-03-25
CA2831480C (en) 2020-09-29
CN104144708A (zh) 2014-11-12
DK2694116T3 (en) 2018-09-03

Similar Documents

Publication Publication Date Title
MX357227B (es) Nanoparticulas basadas en lipidos.
IL245889A0 (en) Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases
CA2865011C (en) Methods and compositions for treating huntington's disease
EP2542255A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE DEGOS SYNDROME
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
MX340055B (es) Metodos y composiciones de nanoparticulas sin priones.
EP2751570A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
IL226377A0 (en) Preparations of isoflavone nanoparticles and methods for their preparation and use
EP2723924A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
EP2480687A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF THYROID CANCER
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2012040331A3 (en) Multistage nanoparticles
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
EP2547666A4 (en) CONJUGATES OF 1,4,7-TRIAZA CYCLONONANES, DINUCLEAR METAL COMPLEXES FROM SUCH CONJUGATES AND METHOD OF USE FOR THE 1,4,7-TRIAZA CYCLONONANES AND THE CONJUGATES
ZA201209452B (en) Gold complexes for use in the treatment of cancer
EP2667896A4 (en) METHOD AND COMPOSITION FOR TREATING MORBUS ALZHEIMER
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
WO2011031833A3 (en) Human anti-cancer antibodies
WO2016068647A3 (ko) 광음향 조영효과 및 항암효과를 나타내는 알부민 나노입자
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease

Legal Events

Date Code Title Description
FG Grant or registration